Alfuzosin hydrochloride
SIGMA/A0232 - ≥98% (HPLC), solid
Synonym: N-
CAS Number: 81403-68-1
Empirical Formula (Hill Notation): C19H27N5O4 · HCl
Molecular Weight: 425.91
MDL Number: MFCD00879135
Linear Formula: C19H27N5O4 · HCl
Product Type: Chemical
| assay | ≥98% (HPLC) |
| form | solid |
| InChI | 1S/C19H27N5O4.ClH/c1-24(8 |
| InChI key | YTNKWDJILNVLGX-UHFFFAOYSA |
| originator | Sanofi Aventis |
| Quality Level | 100 ![]() |
| SMILES string | Cl.COc1cc2nc(nc(N)c2cc1OC |
| solubility | DMSO: >10 mg/mL |
| H2O: insoluble | |
| storage condition | desiccated |
| Biochem/physiol Actions: | Alfuzosin hydrochloride is an alpha-adrenergic blocker used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate. |
| Biochem/physiol Actions: | Alfuzosin hydrochloride is an alpha-adrenergic blocker. |
| Features and Benefits: | This compound is featured on the α1-Adrenoceptors and α2-Adrenoceptors pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Features and Benefits: | This compound was developed by Sanofi Aventis . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 5, 25 mg in glass bottle |
| Hazard Codes | Xn |
| Risk Statements | 22 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| UNSPSC | 12352200 |

